+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 35 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating TQB3107, a targeted inhibitor designed to induce cell death and stop tumor growth, in patients with advanced cancers. This Phase I clinical trial aims to assess the safety and tolerability of TQB3107 tablets, determine dose-limiting toxicities, find the maximum tolerated dose, and recommend a dose for future Phase II studies. Participants receive TQB3107 tablets following one of two dosing schedules either daily for five consecutive days each week with a two-day break per 28-day cycle, or intermittent dosing every 28 days. The study begins with an initial single fasting dose followed by a seven-day observation before continuing the dosing cycles. This design allows researchers to monitor participants closely during the first cycle to assess safety and dosing effects. During the study, participants will have regular assessments including pharmacokinetic blood sampling at multiple time points to measure drug levels, and evaluations of dose-limiting toxicities and maximum tolerated dose at the end of the first 28-day cycle. Longer-term outcomes such as response rates, disease control, progression-free survival, and overall survival will be followed for up to three years. Participants are monitored for up to 24 months for recommended dosing and safety, with comprehensive evaluations throughout the study period.

Age: 18Years - 75YearsAll GendersPhase 1
12 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
E

Actively Recruiting

Researchers are conducting a multicenter, single-arm, open-label phase IaIb clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and early anti-tumor activity of GH56 capsules in subjects with advanced solid tumors that have a deletion of the MTAP gene. The study includes patients who have failed or cannot tolerate standard treatments or have no effective standard therapy, and involves both adult and adolescent cohorts aged 12 years and older. Participants will receive GH56 capsules orally at varying doses during two parts of the study phase Ia dose escalation and phase Ib dose expansion. The dose expansion includes separate adult and adolescent groups and aims to identify the maximum tolerated dose and recommended dose for expansion. Treatment will continue according to the study schedule with close monitoring. During the trial, participants will undergo assessments including tumor measurements using RECIST v1.1 criteria, evaluation of adverse events for safety, laboratory tests for organ function, and pharmacokinetic and pharmacodynamic analyses. Researchers will monitor response rates, disease control, duration of response, and progression-free survival over approximately three years. Pregnancy tests and contraceptive requirements will be followed, and survival expectations must be at least 12 weeks.

Age: 12Years +All GendersPhase 1
25 locations
P

Actively Recruiting

Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.

Age: 18Years +All GendersPhase 3
149 locations
R

Actively Recruiting

Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
186 locations
P

Actively Recruiting

Researchers are studying the effectiveness and safety of combining RC108 with Furmonertinib compared to Furmonertinib alone for treating patients with a specific type of advanced or recurrent non-small cell lung cancer NSCLC that has both EGFR mutations and MET positivity. This phase II clinical trial aims to better understand how these treatments work together for this condition. The trial involves two groups one receiving RC108 combined with Furmonertinib, and the other receiving Furmonertinib alone. Participants have unresectable locally advanced or recurrent metastatic NSCLC with certain EGFR mutations and MET positivity. Treatment and monitoring occur over several months, with careful evaluation of drug effects and safety. Participants will undergo tests for tumor response, survival rates, and disease control over a period of up to 45 months. Researchers will collect tissue samples, monitor side effects, and assess drug levels and immune responses. The study includes regular check-ins to measure how well the cancer responds and to track any adverse events or reactions.

Age: 18Years - 75YearsAll GendersPhase 2
34 locations
E

Actively Recruiting

Bladder cancer is a common and serious tumor that originates from the bladders lining, with the majority being non-muscle invasive bladder cancer NMIBC. NMIBC has a high recurrence rate even after initial treatment, making postoperative bladder perfusion chemotherapy important to prevent tumor return. This research evaluates the use of patient-derived bladder cancer organoids to test drug sensitivities and guide individualized chemotherapy, aiming to improve treatment effectiveness and reduce recurrence for bladder cancer patients. The study involves preparing bladder cancer organoids from tumor tissue collected during surgery. Researchers perform drug sensitivity testing on these organoids with various chemotherapeutic agents, including gemcitabine, pirenzolubicin, epirubicin, mitomycin, and doxorubicin. Based on organoid sensitivity results, patients receive bladder perfusion chemotherapy with either sensitive or non-sensitive drugs, or receive BCG vaccine infusions. Treatment schedules include induction perfusion weekly for 4 weeks and maintenance perfusion monthly for 11 months, or BCG infusions following an induction and maintenance regimen over one year. Participants undergo regular clinical assessments including cystoscopy, urine cytology, and imaging as needed to monitor tumor recurrence and progression over up to three years. Researchers analyze one-year and three-year tumor recurrence-free and progression-free survival rates among groups. The study monitors patient compliance, adverse events, and clinical outcomes to assess the value of organoid drug sensitivity testing in guiding personalized bladder cancer perfusion chemotherapy.

Age: 18Years - 80YearsAll Genders
17 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of ATG-022 compared to Investigators Choice treatment in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who have received prior second-line systemic therapy. This Phase III, randomized, controlled, open-label study involves participants with unresectable locally advanced or metastatic disease who have progressed after at least second-line and no more than fourth-line systemic therapy. The study is based on positive earlier data and aims to compare ATG-022 monotherapy with commonly used chemotherapy options. Participants receive either ATG-022 monotherapy at a dose of 1.8 mgkg every 21 days one cycle or Investigators Choice chemotherapy, which includes either Docetaxel or Irinotecan. Docetaxel is administered at 75-100 mgm every 21 days, while Irinotecan is given at 125 mgm on days 1 and 8 every 21 days. The study uses a parallel design to compare these two treatment regimens. Throughout the trial, participants undergo tumor assessments at baseline and then every 6 weeks during treatment, followed by less frequent evaluations after 12 and 24 months until disease progression or death. Survival follow-up occurs every 3 months until death or study end. Researchers measure progression-free survival, overall survival, objective response rate, disease control rate, and duration of response. Laboratory tests and physical examinations are conducted to monitor organ function and safety. Participants remain in the study until disease progression, death, or study completion, with ongoing monitoring of their health.

Age: 18Years +All GendersPhase 3
131 locations
R

Actively Recruiting

Researchers are studying brenipatide LY3537031 to evaluate its safety, side effects, and effectiveness in adults with Irritable Bowel Syndrome-Constipation IBS-C. The study compares brenipatide given by injection under the skin to a placebo in a phase 2 clinical trial. Participants must meet specific IBS-C criteria and have significant abdominal pain to join. Participants receive the study drug or placebo through subcutaneous injection. The trial lasts about 36 weeks, with treatment and monitoring occurring during this period. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants will keep a daily diary to track symptoms like abdominal pain and bowel movements. Researchers will measure the percentage of weeks participants respond to treatment based on clinical criteria between weeks 9 and 16. Safety and side effects will also be closely monitored throughout the trial.

Age: 18Years - 75YearsAll GendersPhase 2
70 locations
E

Actively Recruiting

Researchers are evaluating the safety, side effects, and effectiveness of brenipatide LY3537031 in adults with Irritable Bowel Syndrome-Diarrhea IBS-D. This study compares brenipatide given under the skin to a placebo and aims to understand how well the drug is tolerated and how it impacts symptoms in participants aged 18 to 75. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Eli Lilly and Company. Participants receive either brenipatide or placebo, both administered subcutaneously. The study follows a parallel design where different groups receive either the experimental drug or the placebo. Treatment and evaluation last approximately 36 weeks, with key outcome measurements focused on symptom responses between weeks 9 to 16 and up to week 24. During the study, participants will record symptoms daily in an electronic diary, including abdominal pain and stool consistency. Researchers will monitor safety, side effects, and symptom changes through these reports and scheduled assessments. The main outcome is the percentage of days participants show significant symptom improvement during the critical weeks of treatment. The study includes a full follow-up period to assess lasting effects and safety throughout the 36 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
89 locations

1-10 of 35

1